ライフサイエンスコーパス: heartburn

1 ents, regardless of the reported severity of heartburn.

2 uncommon in patients who have no history of heartburn.

3 ver age 50, regardless of age or duration of heartburn.

4 lities may help explain their development of heartburn.

5 ree months without symptoms of chest pain or heartburn.

6 d to aspirin (2.5%) experienced drug-related heartburn.

7 ng proven GERD that overlaps with functional heartburn.

8 toms: dysphagia, food impaction, chest pain, heartburn.

9 sent in 74 % of patients with 41 % reporting heartburn.

10 p of 12 months, 93% of patients were free of heartburn.

11 tudy populations by patients with functional heartburn.

12 jects' reports of dysphagia, chest pain, and heartburn.

13 porally related to esophageal chest pain and heartburn.

14 However, only a minority of patients had heartburn (24.3%) or esophagitis (27.4%), and these pati

15 ) and gastroesophageal reflux disease (GERD)/heartburn (27.1%).

16 Children most frequently reported GERD/heartburn (38.1%) and abdominal pain/dyspepsia (31.0%).

17 ir common complaints were bloating (61%) and heartburn (40%).

18 Of 11 patients with heartburn, 6 had erosive esophagitis and 5 had normal-ap

19 considerably lower risks of esophagitis and heartburn (63% relative reduction), dumping syndrome (73

20 = 0.021) were found more frequently, whereas heartburn (76.9% vs. 88.5%; p = 0.046) and regurgitation

21 tinal side effects like indigestion (65.8%), heartburn (78.3%), nausea (48.8%), and regurgitation (52

22 ences of insomnia (2.9% v 0.4%; P < .02) and heartburn (8.1% v 3.6%; P < .03) were significantly grea

23 in 74% of patients with dysphagia, 75% with heartburn, 85% with regurgitation, and 94% with chest pa

24 d dysphagia (96%), food impaction (74%), and heartburn (94%).

25 nt symptoms were chest pain (131, 31.9%) and heartburn (97, 23.6%).

26 en ferrous sulphate and placebo groups were: heartburn, abdominal pain and the presence of black stoo

27 a (large cell type) presented with diarrhea, heartburn, abdominal pain, and duodenal ulcers.

28 f ferrous iron salts (i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and constipation).

29 ed symptoms were dysphagia (70% and 86%) and heartburn/acid reflux (55% and 49%), and common physicia

30 Overall, BE was not associated with heartburn, although heartburn was more common in persons

31 commonly offered to patients with functional heartburn, although supportive clinical studies are stil

32 Forty-six patients with heartburn and 10 healthy controls underwent upper endosc

33 Heartburn and acid regurgitation are significantly assoc

34 iastolic blood pressure and the frequency of heartburn and acid regurgitation in 4,902 of 10,537 part

35 Heartburn and acid regurgitation were associated with no

36 Heartburn and acid taste were more commonly linked to ac

37 endoscopy is indicated in men and women with heartburn and alarm symptoms (dysphagia, bleeding, anemi

38 Both heartburn and chest pain were included in the oesophagea

39 exposure ranges from no perception to severe heartburn and chest pain.

40 ed what they would do if they had bothersome heartburn and could have either drug for free, 68% of th

41 Most patients with GERD present with heartburn and effortless regurgitation.

42 sis of baseline data on the severity of both heartburn and erosive esophagitis pooled data from 5 pro

43 ions that can mimic GERD, such as functional heartburn and hypersensitive esophagus as well as, more

44 icrons were present in 8 of 11 patients with heartburn and in no controls.

45 cantly decreased in patients with or without heartburn and in those with symptoms suggestive of FD an

46 geal reflux disease (GERD) is much more than heartburn and patients constitute a heterogeneous group.

47 rrelated positively with symptom severity of heartburn and regurgitation (p < .001).

48 Heartburn and regurgitation are considered classic sympt

49 ERD) is defined by recurrent and troublesome heartburn and regurgitation or GERD-specific complicatio

50 y analysis for prevalence of all types GERD, heartburn and regurgitation symptoms by removing a study

51 phagus patients reported more severe typical heartburn and regurgitation symptoms than either control

52 tively, were satisfied with the treatment of heartburn and regurgitation symptoms, a secondary variab

53 erized by troublesome symptoms (classically, heartburn and regurgitation).

54 Symptoms are defined typical, as heartburn and regurgitation, and atypical (also called e

55 ux episodes) were seen in 32.6% and 40.5% of heartburn and regurgitation-predominant patients, respec

56 ptoms of gastroesophageal reflux disease are heartburn and regurgitation.

57 es have no therapeutic benefit in functional heartburn and should not be recommended.

58 were inquired about the dyspeptic symptoms (heartburn and/or acid regurgitation and/or dysphagia).

59 The prevalence per 100 of heartburn and/or acid regurgitation experienced at least

60 NCT00703534) had frequent (>/= 3 days/week) heartburn and/or regurgitation despite PPI therapy; pati

61 Symptoms like vomiting, heartburn, and headaches were linked to a transition fro

62 h heartburn-free period in moderate episodic heartburn, and is a relevant effective alternative treat

63 Treatments for PPI-refractory heartburn are of unproven efficacy and focus on controll

64 tion of the definition of reflux-associated "heartburn" as an acid-mediated event requiring "relief b

65 Clinical outcomes were similar, except less heartburn at 3 and 6 months and less bloating at 12 mont

66 g at 12 months with nonabsorbable mesh; more heartburn at 3 months, odynophagia at 1 month, nausea at

67 omes were the proportion of patients without heartburn by D7, pain relief by D7, and reduction in pai

68 symptom severity (dysphagia, regurgitation, heartburn, chest pain) preoperatively and postoperativel

69 A year or more after revision operation, heartburn, chest pain, and dysphagia were rare or absent

70 Seventy-four subjects with heartburn completed a URS questionnaire before dual-prob

71 The presence of heartburn decreased from 94.2% to 33.7% (P<0.001), regur

72 Further adjustment for frequency of heartburn did not change these results.

73 d for the symptomatic treatment of nocturnal heartburn due to gastroesophageal reflux disease, was ap

74 xcluded 288 patients: 42 had relief of their heartburn during the 2-week omeprazole trial, 70 did not

75 reflux-unrelated problems such as functional heartburn, dyspepsia or even eosinophilic oesophagitis.

76 prazole (20 mg/day) in patients with 2-6 day heartburn episodes weekly without alarm signals.

77 esophageal mucosa with acid, before inducing heartburn, evokes a cerebral cortical response detectabl

78 oup study enrolled adults with NERD who were heartburn-free after 4 weeks' treatment with esomeprazol

79 y resulted in significantly longer period of heartburn-free days (23 vs 12 days on omeprazole).

80 nalyses showed vonoprazan was noninferior in heartburn-free days (difference, 2.7%; 95% CI, -1.6% to

81 The mean number of heartburn-free days by D7 was significantly greater in t

82 The mean time to onset of the first 24-h heartburn-free period after initial dosing was 2.0 (+/-

83 was the mean time to onset of the first 24-h heartburn-free period after initial dosing.

84 n-inferior to omeprazole in achieving a 24-h heartburn-free period in moderate episodic heartburn, an

85 ed because patients with endoscopy-negative "heartburn" have lower response rates to acid suppression

86 ars with no prior endoscopy, irrespective of heartburn history.

87 rs than do patients with endoscopy-positive "heartburn," ie, erosive esophagitis.

88 se of GERD subgroups must exclude functional heartburn if NERD is to be properly understood.

89 Heartburn improved in 94 (96%) of 98 and resolved in 69

90 Chest pain and heartburn improved significantly (p < 0.01) as well.

91 aled truly PPI-refractory and reflux-related heartburn in a minority of patients.

92 , weekly, monthly, and overall prevalence of heartburn in Iranian population was 2.46% (95%CI: 0.93-6

93 conclusions drawn about the pathogenesis of heartburn in nonerosive reflux disease is a reaffirmatio

94 & AIMS: Little is known about the causes of heartburn in patients with gastro-esophageal reflux dise

95 Management of heartburn in pregnant and breastfeeding women involves l

96 e been proposed to explain the occurrence of heartburn in the endoscopy-negative setting.

97 Heartburn is a symptom complex that has traditionally be

98 phagitis increases with age, the severity of heartburn is an unreliable indicator of the severity of

99 oma from Barrett metaplasia dictates that if heartburn is refractory to treatment, chronic (>5 years)

100 Although heartburn is the most common symptom of reflux disease,

101 After anterior fundoplication heartburn (mean score 3.2 vs 1.4, p = 0.001) and proton

102 iver function test results, fever, headache, heartburn, nausea, vomiting, peripheral and central neur

103 esophageal disorders, and 99 had functional heartburn (not due to GERD or other histopathologic, mot

104 Heartburn occurring at least weekly was reported in 27%,

105 Patients consulting physicians because of heartburn or acid regurgitation were recruited at 926 pr

106 efit as either primary therapy in functional heartburn or as add-on therapy in functional heartburn t

107 Acid perfusion did not induce heartburn or chest pain but increased FMRI signal intens

108 frequent in the vagal nerve block group were heartburn or dyspepsia and abdominal pain attributed to

109 n the past and persistence of GERD symptoms (heartburn or regurgitation 2 or more days in past week)

110 m requiring device removal was recurrence of heartburn or regurgitation in 5 patients (46%), followed

111 Also, patients often present without heartburn or regurgitation typical of GERD.

112 se among individuals who ever smoked and had heartburn or regurgitation was estimated to be 0.39 (95%

113 The age-adjusted prevalence of heartburn or regurgitation was not significantly differe

114 For weekly heartburn or regurgitation, black participants had signi

115 Smoking has synergistic effects with heartburn or regurgitation, indicating that there are va

116 exposure had typical reflux symptoms such as heartburn or regurgitation.

117 idence of a synergy between ever-smoking and heartburn or regurgitation; the attributable proportion

118 ay have benefit as monotherapy in functional heartburn, or as adjunctive therapy combined with other

119 ith LSBE patients having a longer history of heartburn (P </= 0.009).

120 n those with any heartburn vs. those with no heartburn (P = 0.01), but the sample size was insufficie

121 Twelve heartburn patients underwent two 2-hour studies of intra

122 diagnosed according to Rome IV criteria when heartburn persists despite maximal PPI therapy in patien

123 roesophageal reflux disease (GERD) (European heartburn-predominant cohort: n = 43, median age 57.0 ye

124 gastroenterology clinics for PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2

125 Heartburn received the highest score among GORD symptoms

126 scomfort scores were reported in the Reflux (heartburn, regurgitation), Indigestion, and Abdominal pa

127 The presence of heartburn, regurgitation, abnormal levels of esophageal

128 the western world has been linked to chronic heartburn, regurgitation, and the development of the pre

129 ults with troublesome esophageal symptoms of heartburn, regurgitation, and/or chest pain and inadequa

130 nificant reduction in all measured symptoms (heartburn, regurgitation, dysphagia, chest pain, early s

131 85 to 2015 and included the following terms: heartburn, regurgitation, dysphagia, gastroesophageal re

132 he search terms included were the following: heartburn, regurgitation, dysphagia, gastroesophageal re

133 asymptomatic; however, symptoms may include heartburn, regurgitation, dysphagia, nausea, or vague ep

134 All other symptom scores including heartburn, regurgitation, respiratory symptoms, and pain

135 sease, it is unclear whether the severity of heartburn reliably indicates the severity of erosive eso

136 PRACTICE ADVICE 2: A diagnosis of functional heartburn requires upper endoscopy with esophageal biops

137 13%; RR: 1.42; 95% CI: 0.69-2.91; P = 0.34), heartburn score (standardized mean difference: 1.27; 95%

138 The mean heartburn score was 2.3 (0, best; 45, worst); the satisf

139 were esophageal acid exposure, esophagitis, heartburn score, dilatation for dysphagia, modified Dakk

140 The 5-year heartburn score, dilatation rate, reoperation rate, PPI

141 Reflux control, measured by heartburn scores and antisecretory medication use, was s

142 Follow-up included heartburn scores and quality of life measurements using

143 id not have higher dysphagia scores or lower heartburn scores than the no wrap group.

144 Chest pain, dysphagia, and heartburn scores were not significantly different.

145 phagitis are similar, with no differences in heartburn scores, patient satisfaction, dilatations, and

146 on, which was accompanied by higher clinical heartburn scores.

147 FP decreased heartburn severity (P = .041).

148 ent change from baseline to week 8 in weekly heartburn severity score.

149 an changes from baseline to week 8 in weekly heartburn severity scores were reductions of 46.0% in th

150 PRACTICE ADVICE 1: A diagnosis of functional heartburn should be considered when retrosternal burning

151 active vs. sham patients were without daily heartburn symptoms (n = 19 [61%] vs. n = 7 [33%]; P = 0.

152 icantly and substantially improved patients' heartburn symptoms and quality of life.

153 718 to label-dose PPIs significantly reduced heartburn symptoms compared with adding placebo.

154 Acute auditory stress can exacerbate heartburn symptoms in GERD patients by enhancing percept

155 Postoperative heartburn symptoms were reported as "moderate to severe"

156 ssessed the relationship between age, severe heartburn symptoms, and severe erosive esophagitis.

157 Risk factors such as increasing age, heartburn symptoms, increasing length of Barrett's segme

158 gastroenterology clinics for PPI-refractory heartburn, systematic workup revealed truly PPI-refracto

159 ntly greater in specimens from patients with heartburn than those from controls; this was true irresp

160 heartburn or as add-on therapy in functional heartburn that overlaps with proven GERD.

161 Heartburn that persists despite proton-pump inhibitor (P

162 PPIs have no therapeutic value in functional heartburn, the exception being proven GERD that overlaps

163 Among 556 subjects who had never had heartburn, the prevalences of BE and LSBE were 5.6% and

164 Among 384 subjects with a history of any heartburn, the prevalences of BE and LSBE were 8.3% and

165 vealed younger age and a dominant symptom of heartburn to predict PPI requirement.

166 ancer have been described, including chronic heartburn, tobacco use, white race, and obesity.

167 daily for 2 weeks, and those with persistent heartburn underwent endoscopy, esophageal biopsy, esopha

168 ysis, LSBE was more common in those with any heartburn vs. those with no heartburn (P = 0.01), but th

169 One year after operation, heartburn was absent in 93%.

170 In class 4, heartburn was also identified and more atypical digestiv

171 ong patients with severe esophagitis, severe heartburn was less frequent in the older age groups: ran

172 was not associated with heartburn, although heartburn was more common in persons with LSBE or circum

173 f patients were found to have reflux-related heartburn, we randomly assigned them to receive surgical

174 with (n = 11) and without (n = 13) recurrent heartburn were examined using transmission electron micr

175 ction with simple analgesics, nausea, and no heartburn were independent predictors of clinically rele

176 e patients with at least a 1-year history of heartburn with a normal endoscopy or grade A esophagitis

177 nt, however, this should be considered to be heartburn with and without regurgitation due to gastroes

178 EST PRACTICE ADVICE 3: Overlap of functional heartburn with proven GERD is diagnosed according to Rom